SCHEMBL6923601

SCHEMBL6923601

Clc1cccc(Nc2coc3cccnc23)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 3/20 0.58
FADS1 O60427 3/20 0.49
HPGD P15428 2/20 0.45
NPC1 O15118 1/20 0.45
HTT P42858 1/20 0.45
ERBB2 P04626 3/20 0.43
PTK6 Q13882 3/20 0.43
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
HTR3A P46098 1/20 0.43
ROCK1 Q13464 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.41
HDAC6 Q9UBN7 1/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
ABL1 P00519 1/20 0.40
BCR P11274 1/20 0.40
PRKCA P17252 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6923811 0.83 GRM4 (0.43) GRM4HPGDNPC1PTGS2ALDH1A1
SCHEMBL2235375 0.77 GRM4 (0.58) GRM4FADS1HPGDNPC1HTT
Hydrochloric Acid SCHEMBL2234357 0.76 GRM4 (0.56) GRM4FADS1HPGDNPC1HTT
SCHEMBL30918025 0.76 FADS1 (0.59) FADS1HPGDNPC1ERBB2PTK6
SCHEMBL2361084 0.73 GRM4 (1.00) GRM4FADS1HPGDNPC1HTT
SCHEMBL3955378 0.73 GRM4 (0.56) GRM4FADS1HPGDNPC1HTT
SCHEMBL24172046 0.72 HSP90AA1 (0.35) HPGDNPC1HTTIDO1
SCHEMBL3951245 0.71 HDAC6 (0.58) GRM4FADS1HPGDNPC1HTT
SCHEMBL4738631 0.71 FADS1 (0.83) GRM4FADS1ERBB2PTK6ABCG2
SCHEMBL3377751 0.70 GRM4 (0.59) GRM4FADS1HPGDNPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916584-B2 Benzisoxazoles and azabenzisoxazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction VANDERBILT UNIVERSITY (US) 2014-12-23 US disclosed
US-8916584-B2 Benzisoxazoles and azabenzisoxazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction VANDERBILT UNIVERSITY (US) 2014-12-23 US disclosed
US-20130079366-A1 Benzisoxazoles and Azabenzisoxazoles as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction VANDERBILT UNIVERSITY (US) 2013-03-28 US disclosed
US-20130079366-A1 Benzisoxazoles and Azabenzisoxazoles as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction VANDERBILT UNIVERSITY (US) 2013-03-28 US disclosed
WO-2011100614-A1 BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY (US) 2011-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079366-A1 Benzisoxazoles and Azabenzisoxazoles as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction GRIK4, GRM4, GRIA4 GRM4 2/4885FADS1 4074/4885HPGD 2936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.